Immunic, Inc. (IMUX) |
1.23 -0.03 (-2.38%) 04-26 12:02 |
Open: | 1.26 |
High: | 1.28 |
Low: | 1.19 |
Volume: | 162,268 |
Market Cap: | 111(M) |
PE Ratio: | -0.58 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 1.46 |
Resistance 1: | 1.35 |
Pivot price: | 1.29 |
Support 1: | 1.17 |
Support 2: | 0.97 |
52w High: | 3.11 |
52w Low: | 0.945 |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
EPS | -2.110 |
Book Value | 0.640 |
PEG Ratio | -0.08 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -68.1 |
Return on Equity (ttm) | -131.3 |
Thu, 11 Apr 2024
Immunic, Inc. (NASDAQ:IMUX): When Will It Breakeven? - Simply Wall St
Fri, 05 Apr 2024
Brookline Capital starts Immunic at buy, cites MS drug candidate (NASDAQ:IMUX) - Seeking Alpha
Thu, 04 Apr 2024
Immunic to Host MS R&D Day and Participate in Investor Conferences in April - Yahoo Finance
Thu, 04 Apr 2024
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors - Yahoo Finance
Thu, 29 Feb 2024
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum ... - PR Newswire
Thu, 29 Feb 2024
Immunic And 2 Other Stocks Under $2 Insiders Are Buying - Markets Insider
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |